RLT Platform

Cost-Effectiveness Analysis

Compare Lu-177-PSMA therapy with standard treatments using a literature-parameterized CEA model (QALY and ICER). Survival inputs are inspired by VISION and TheraP; costs and utilities are configurable and should be adapted to local data. Method note: Includes Weibull survival modeling, region presets, and probabilistic sensitivity analysis (PSA; Monte Carlo, 10,000 iterations by default).

Treatment Comparison Setup

Select region for appropriate pricing and discount rates

Recommended: 5-year or lifetime horizon for mCRPC

EU: 3.5% (EMA/NICE guidance)

EU threshold: EUR 50,000/QALY typical

Note: Subsequent therapy costs can materially affect total costs in mCRPC; include unless you have a defensible local assumption.

ICER Analysis

Methods & Sources (Summary)

MODEL NOTES

  • Perspective: Healthcare system (default). Region presets are illustrative—replace with local reimbursement/formulary data for real decisions.
  • Survival: Parametric Weibull-style modeling inspired by VISION / TheraP trial publications.
  • Uncertainty: Probabilistic Sensitivity Analysis (PSA) via Monte Carlo sampling (default 10,000 iterations). “PSA” here means sensitivity analysis, not prostate-specific antigen.
  • Utilities: QALY utilities are assumptions unless cited for your target population and setting.

Key references (starting points)

  • TheraP secondary outcomes (Lancet Oncology, 2023): PMID 38043558
  • Example Lu-177-PSMA-617 cost-utility analysis (Germany, 2025): PMCID PMC12491114
  • ISPOR-SMDM good practices on parameter uncertainty / PSA: PMID 22990087

If you need a defensible “validated” claim, it must be tied to a specific published CEA/HTA with matching structure + parameters + outputs.

Detailed Breakdown